SCHEMBL4928558

SCHEMBL4928558

COc1ccc(C(/C=N/O)=N/NC(=O)c2ccccc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.62
NPC1 O15118 5/20 0.62
MAPT P10636 5/20 0.55
ALDH1A1 P00352 4/20 0.55
HTT P42858 3/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
MAOA P21397 2/20 0.55
MAOB P27338 2/20 0.55
LMNA P02545 2/20 0.55
KDM4E B2RXH2 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
KMT2A Q03164 4/20 0.53
MEN1 O00255 3/20 0.53
GAA P10253 3/20 0.53
SENP6 Q9GZR1 1/20 0.49
KCNK9 Q9NPC2 1/20 0.49
CES2 O00748 1/20 0.49
CES1 P23141 1/20 0.49
CYP1A2 P05177 1/20 0.48
GFER P55789 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4928562 1.00 RAB9A (0.62) RAB9ANPC1MAPTALDH1A1HTT
SCHEMBL4882658 1.00 RAB9A (0.62) RAB9ANPC1MAPTALDH1A1HTT
SCHEMBL4882668 1.00 RAB9A (0.62) RAB9ANPC1MAPTALDH1A1HTT
SCHEMBL5715915 0.87 NPC1 (0.53) RAB9ANPC1MAPTALDH1A1SMN1; SMN2
SCHEMBL5715919 0.87 NPC1 (0.53) RAB9ANPC1MAPTALDH1A1SMN1; SMN2
SCHEMBL4881966 0.87 NPC1 (0.57) RAB9ANPC1MAPTALDH1A1HTT
SCHEMBL4887230 0.87 NPC1 (0.57) RAB9ANPC1MAPTALDH1A1HTT
SCHEMBL4887228 0.87 NPC1 (0.57) RAB9ANPC1MAPTALDH1A1HTT
SCHEMBL4881965 0.87 NPC1 (0.57) RAB9ANPC1MAPTALDH1A1HTT
SCHEMBL4882310 0.86 MAOA (0.55) RAB9ANPC1MAPTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080227787-A1 Use of New Lipoxygenase Inhibitors BIOLIPOX AB (SE) 2008-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227787-A1 Use of New Lipoxygenase Inhibitors ALOX15, ALOX15B, ALOX12 RAB9A 3811/4885NPC1 2644/4885MAPT 4603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.